^
    Back
    Association details:
    Biomarker:PIK3CA G1049R + AKT1 E17K
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    1968p - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

    Published date:
    09/14/2020
    Excerpt:
    ...advanced NSCLC patients before dabrafenib and trametinib treatment were included...Patients with a concurrent PIK3CA p.(G1049R) or AKT1 p.(E17K) mutation had a relatively short PFS of 4 and 3 months…